BioStem Technologies Free Cash Flow (FCF) History (BSEM)
BioStem Technologies reported $9.9M in free cash flow for fiscal 2025, a decrease of 59.37% from the previous fiscal year, with a free cash flow margin of 20.94%.
View full BioStem Technologies company overviewBioStem Technologies free cash flow by year
2021
2022
2023
2024
2025
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.9M | −$14.5M | −59.37% | +20.94% |
| 2024 | 2024-12-31 | $24.5M | $28.2M | — | +35.12% |
| 2023 | 2023-12-31 | −$3.7M | −$3.5M | — | −22.23% |
| 2022 | 2022-12-31 | −$165,909 | −$13,622 | — | −2.41% |
| 2021 | 2021-12-31 | −$152,287 | — | — | −3.51% |
BioStem Technologies quarterly free cash flow
Q4.24
Q3.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | −$4.8M | — | — | −45.84% |
| Q4 2024 | 2024-12-31 | $8.0M | — | — | +7.80% |
BioStem Technologies free cash flow growth trends
BioStem Technologies's latest reported quarter, Q3 2025, generated −$4.8M in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review BioStem Technologies source filings ↗